PIPELINE

Acepodia is applying its ACC™ technology to arm immune cells with antibodies to direct and evoke immune responses to eradicate cancer cells.

Target

 Indication                       

Discovery           

Pre-Clinical 

IND

Lung cancers, melanoma, head and neck cancer, and other carcinomas

PD-L1

Endometrial cancer, ovarian cancer, breast cancer, gastric cancer

ACE1708

oNK Line        

ACE1702

HER2

Clinical

ACE1755

CD19

CD20

B-cell lymphoma, chronic
lymphocytic leukemia

Programs

ACE1702

Acepodia’s leading clinical product candidate, ACE1702, targets human HER2-expressing solid tumors using anti-HER2 conjugated oNK cells. ACE1702 has demonstrated enhanced tumor cell killing activities both in vitro and in vivo, while maintaining a favorable safety profile in GLP toxicology studies. In preclinical studies ACE1702 has shown enhanced tumor kill efficacy against HER2 IHC 1+, 2+ and 3+ cancer cells, which may have broader coverage on different HER2 expression level carcinoma in treatment compared to Herceptin. 

ACE1708

ACE1708, an anti-PD-L1 targeting oNK cell product has shown outstanding anti-tumor activities toward non-small cell lung cancer, bladder cancer, and several additional cancer types with low to high PD-L1 expression in vitro. ACE1708 is a first-in-class immunotherapy which harnesses both NK and T cell capabilities with potential for targeting any PD-L1-expressing cancers.

Target

 Indication                       

Discovery           

Pre-Clinical 

IND

Lymphoma and Leukemia and other liquid tumors

N/A

Multiple Myeloma

ARC1755g

gdT Line        

AAT1805

N/A

Clinical

"We believe what we do is important to the challenges and opportunities of current health care and industries.”

SONNY HSIAO, CEO OF ACEPODIA

Acepodia Logo

Acepodia Taiwan

Rm. 7, 17F., No.99, Sec. 1, Sintai 5th Rd., Sijhih Dist., 

New Taipei City 22175, 

Taiwan (R.O.C.)

 

Acepodia USA

Burlingame, California USA

Tel:  +886-2-26976100 
info@acepodiabio.com

LinkedIn-icon.png
Twitter-icon.png

© 2018 Acepodia Inc.

All rights reserved